The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2014
DOI: 10.1007/s13311-013-0247-9
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Restless Legs Syndrome

Abstract: Restless legs syndrome (RLS) is a common disorder diagnosed by the clinical characteristics of restlessness in the legs associated often with abnormal sensations that start at rest and are improved by activity, occurring with a diurnal pattern of worsened symptoms at night and improvement in the morning. RLS is the cause of impaired quality of life in those more severely afflicted. Treatment of RLS has undergone considerable change over the last few years. Several classes of medications have demonstrated effic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
31
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 40 publications
(33 citation statements)
references
References 114 publications
0
31
0
Order By: Relevance
“…The first such agent shown to be successful in the treatment of RLS was levodopa [12]; this dopamine precursor is still used occasionally in some European countries, namely Germany, Austria and Switzerland, mainly for the on-demand treatment of intermittent (as opposed to daily) RLS symptoms [9]. Although initially effective, the usefulness of dopaminergic agents may be limited by subsequent loss of efficacy (tolerance) and adverse events, including daytime sleepiness, impulse control disorders and the development of augmentation [13].…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…The first such agent shown to be successful in the treatment of RLS was levodopa [12]; this dopamine precursor is still used occasionally in some European countries, namely Germany, Austria and Switzerland, mainly for the on-demand treatment of intermittent (as opposed to daily) RLS symptoms [9]. Although initially effective, the usefulness of dopaminergic agents may be limited by subsequent loss of efficacy (tolerance) and adverse events, including daytime sleepiness, impulse control disorders and the development of augmentation [13].…”
Section: Introductionmentioning
confidence: 99%
“…Although initially effective, the usefulness of dopaminergic agents may be limited by subsequent loss of efficacy (tolerance) and adverse events, including daytime sleepiness, impulse control disorders and the development of augmentation [13]. The latter, which is characterized by an overall worsening in RLS symptom severity compared with the pretreatment level, represents the most important long-term complication of dopaminergic treatment [9,12]. Although augmentation is most common during long-term treatment with levodopa (up to 60 % of patients), it is still a frequent occurrence during long-term treatment with NEDAs (up to 40 % of patients) [10,12].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…88 In addition, symptomatic relief may be achieved with antiepileptic agents, opioids, and benzodiazepines. [89][90][91] Augmentation of RLS by dopaminergic and other agents 63-65 occurs usually after prolonged administration, 89 suggesting that pathogenic imbalance persists in new steady state activities of these neurotransmitters. Muscle quietness is similarly disturbed either by administration or withdrawal of antidopaminergic, antihistaminic, antidepressant, antipsychotic, and anticonvulsant agents, consistent with the concept that oscillations in neuromodulation are in fact involved in the mechanism of RLS.…”
Section: Interpretation Of the Proposed Mechanismmentioning
confidence: 99%
“…While no phase III trials have been completed, Cloud et al [15] present data on therapy with a focus on those drugs with evidence from phase II double-blind trials, such as tetrabenazine, amantadine, levetiracetam, clonazepam, and gingko biloba. Comella [16] presents the current status of restless leg syndrome and the evidence for dopaminergic agents and the alpha-2-delta ligands, as well as other older medications, such as opiates and benzodiazepines. Myoclonus therapy, as reviewed by Caviness [17], should be guided by neurophysiologic classification.…”
mentioning
confidence: 99%